Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
Median overall survival (mOS) and median progression-free survival... | Download Scientific Diagram
a) Median progression-free survival (PFS) to second-line (SL) therapy.... | Download Scientific Diagram
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open
Percentage Progression-free survival and overall survival on treatment.... | Download Scientific Diagram
Overall survival and progression-free survival. The median follow-up... | Download Scientific Diagram
Diagnostics | Free Full-Text | Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small
Progression Free Survival Curve. Median PFS 4.5 months 95% CI 3.5–5.3.... | Download Scientific Diagram
Kaplan-Meier analysis of (a) progression-free survival (PFS); and (b)... | Download Scientific Diagram
Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms in: Endocrine-Related Cancer Volume 24 Issue 9 (2017)
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy | BMC Cancer | Full
A) Overall survival (OS) and (B) progression-free survival (PFS).... | Download Scientific Diagram
Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis | PLOS ONE
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study | Leukemia
OVERALL AND PROGRESSION-FREE SURVIVAL IN PATIENTS TREATED WITH.... EHA Library. Harrison C. Jun 9 2021; 324611
Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates | Journal for ImmunoTherapy of Cancer
Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects | Nature Communications
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer